Erasca ERAS 深 沪
已收盘 10-30 16:00:00 美东时间
14.35
-0.630
-4.21%
华盛通- 最 高15.01
- 今 开14.66
- 成交量 374.95万股
- 最 低 14.035
- 昨 收 14.98
- 总市值 50.19亿
- 52周最高 24.28
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 2.21
- 委 比 -37.19%
- 总股本 3.50亿
- 历史最高 24.47
- 量 比 0.87
- 振 幅 6.51%
- 历史最低 1.01
- 每 手 1
- 风险率 5.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
Propanc Biopharma announced new preclinical data supporting PRP's potential to address chemotherapy resistance in pancreatic cancer. PRP, a proprietary enzyme formulation, demonstrated anti-tumor activity, EMT reversal, and chemosensitization in preclinical models. Key findings include reduced cancer cell proliferation, inhibited metastasis, and enhanced response to chemotherapy. PRP's mechanism targets cancer stem cells and fibrosis, complementi...
10-26 12:30
Erasca realigns leadership to focus RAS oncology programs
Erasca ( ($ERAS) ) just unveiled an update. On October 15, 2026, Erasca, Inc. a...
10-16 21:38
美股牛股 | Pacira BioSciences暴升44%，获Viatris16.5亿美元收购；Haemonetics升逾17%，CSL拟于27年底前部署NexSys PCS血浆采集设备
Pacira BioSciences暴升44%，获Viatris16.5亿美元收购；Haemonetics升逾17%，CSL拟于27年底前部署NexSys PCS血浆采集设备>>
10-09 18:33
Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of lead candidate PRP against recently reported clinical datase...
09-22 20:34
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Erasca, Inc., a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference in New York. Management will engage in a fireside chat on September 15, 2026, at 1:05 pm ET and hold one-on-one investor meetings. A live audio webcast and a 30-day replay will be available on Erasca.com/events. The company aims to erase cance...
09-08 11:00
Erasca Wins FDA Fast Track for Pancreatic Therapy
Erasca ( ($ERAS) ) has shared an announcement. On August 24, 2026, Erasca, Inc....
08-24 20:48
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Erasca's ERAS-0015, a pan-RAS molecular glue targeting RAS/MAPK pathway-driven cancers, has received FDA Fast Track Designation for treating metastatic pancreatic adenocarcinoma. The drug showed a 57% uORR in 2L+ KRAS G12X pancreatic cancer patients in Phase 1 trials, with favorable tolerability. Erasca plans three potentially registration-enabling trials in pancreatic and lung cancers, aiming to advance ERAS-0015's development. The designation s...
08-24 12:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
